Takeda, Amylin Of U.S. Cancel Co-Development Of Obesity Drug
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceuticals and its development partner, U.S.-based Amylin Pharmaceuticals, said they are canceling their joint development of an anti-obesity drug